Table 2.

Summary of TEAEs with telisotuzumab occurring in ≥10% of patients, and telisotuzumab TRAEs occurring in ≥5% of patients.

TEAEs TelisotuzumabTRAEs Telisotuzumab
Any gradeGrade ≥3Any gradeGrade ≥3
n (%)n (%)n (%)n (%)
All dosesExpansion cohortAll dosesExpansion cohortAll dosesExpansion cohortAll dosesExpansion cohort
Adverse event(N = 45)(N = 30)(N = 45)(N = 30)(N = 45)(N = 30)(N = 45)(N = 30)
Any TEAE42 (93.3)28 (93.3)20 (1.7)13 (43.3)22 (48.9)12 (40.0)3 (6.7)0
 Constipation13 (28.9)8 (26.7)1 (2.2)1 (3.3)0000
 Fatigue12 (26.7)8 (26.7)005 (11.1)3 (10.0)00
 Decreased appetite9 (20.0)7 (23.3)003 (6.7)2 (6.7)00
 Hypoalbuminemia12 (26.7)6 (20.0)4 (8.9)1 (3.3)9 (20.0)4 (13.3)2 (4.4)0
 Peripheral edema12 (26.7)5 (16.7)004 (8.9)1 (3.3)00
 Hypokalemia10 (22.2)5 (16.7)1 (2.2)1 (3.3)1 (2.2)000
 Nausea10 (22.2)5 (16.7)2 (4.4)1 (3.3)2 (4.4)2 (6.7)00
 Vomiting9 (20.0)5 (16.7)1 (2.2)1 (3.3)1 (2.2)1 (3.3)00
 Anemia7 (15.6)5 (16.7)2 (4.4)1 (3.3)2 (4.4)1 (3.3)00
 Abdominal pain6 (13.3)5 (16.7)000000
 Back pain6 (13.3)4 (13.3)000000
 Dyspnea6 (13.3)4 (13.3)1 (2.2)1 (3.3)0000
 Abdominal distension5 (11.1)4 (13.3)001 (2.2)1 (3.3)00
 Diarrhea5 (11.1)4 (13.3)002 (4.4)2 (6.7)00
 Ascites6 (13.3)3 (10.0)1 (2.2)1 (3.3)0000
 Pruritus5 (11.1)3 (10.0)001 (2.2)000
  • Abbreviations: TEAE, treatment-emergent adverse event; TRAE, treatment-related adverse event.